News and Announcements
Grow Alpha Fund produces return of +3.13% in first quarterly performance
- Published October 26, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Grow Alpha Fund’s first quarterly performance has produced a gross return of +3.13%.
- Grow Alpha’s incubation fund has produced a YTD 2018 gross return of +21.68%.
- The Grow Alpha Fund has a strong investment management team with over 2 decades of investment trading experience.
Grow Alpha are pleased to report that their Grow Alpha Fund’s first quarterly performance has produced a gross return of +3.13%.
The Grow Alpha Fund has a strong investment management team with over 2 decades of investment trading experience.
It is managed by a 8-step Quantitative methodology which embodies best-in-class practices in Cyclical Analysis, Price Behavior, Momentum Analysis, Portfolio Management, Proprietary Synchronized Synergies, Scalability, Prudent Leverage and Risk Management.
Furthermore, Grow Alpha’s incubation fund has produced a YTD 2018 gross return of +21.68% and since inception, a gross return of +151.56%.
Key Features of the Grow Alpha Fund:
- No management fee
- 20% performance fee on high watermark basis
- For wholesale investors only
- Long/Short US Equities & Derivatives’ Fund
About Grow Alpha Capital Pty Ltd
GROW ALPHA FUND, a Quantitative 8-step US Equities Long/Short Fund: No Management Fee. 20% Performance Fee on a high watermark basis. Targeting 50% p.a. net return with a drawdown of 25%. 60.33%* p.a. net return with moderate volatility of 14.6%* (*Past Performance may not be indicative of future performance.)
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
